Therapeutic strategies to increase high-density lipoprotein (HDL) to treat or prevent vascular disease include the use of cholesteryl-ester transfer protein (CETP) inhibitors. Here, we show, to the best of our knowledge for the first time, that addition of CETP to HDL enhances the ability of HDL to
Metabolic fate of low density lipoprotein and high density lipoprotein labeled with an ether analogue of cholesteryl ester
β Scribed by Stein, O. ;Stein, Y. ;Coetzee, G. A. ;Westhuyzen, D. R.
- Publisher
- Springer-Verlag
- Year
- 1984
- Tongue
- English
- Weight
- 574 KB
- Volume
- 62
- Category
- Article
- ISSN
- 1432-1440
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
This study examines the effect of mutation of the low-density lipoprotein receptor (LDLR) on cholesterol metabolism, and especially lipoprotein-derived cholesteryl ester uptake, in murine ovarian granulosa cells. Although the tests were conducted on cells prepared by two different procedures, the re
High plasma concentrations of high-density lipoprotein (HDL) cholesterol are a powerful indicator of low vascular risk. By decreasing HDL cholesterol, cholesteryl ester transfer protein (CETP) could perhaps constitute an atherogenic protein. We measured HDL cholesterol and HDL subfractions and quant
## Abstract Diethylumbelliferyl phosphate (UBP) has been shown to inhibit the neutral cholesteryl ester hydrolase activity responsible for hydrolysis of cellular lipid droplet cholesteryl ester (Harrison et al., 1990). The potential for (UBP) to inhibit uptake and hydrolysis of high density lipopro